Gene: PGAP3

93210
AGLA546|CAB2|PERLD1|PP1498|hCOS16
post-GPI attachment to proteins 3
protein-coding
17q12
Ensembl:ENSG00000161395 MIM:611801 Vega:OTTHUMG00000179110 UniprotKB:Q96FM1
NG_034125.1
PubMed
0   ANCO-SNPs
ND
1   
NA (AD)  NA (ND)   (Frontal_Cortex)
7.816e-1 (AD)  6.945e-1 (ND)

DNA Methylation

Probe Locus(GRCh37) Gene Region p-val Trait PubMed ID
cg19758448chr17:37828296PGAP31.200e-10Smoking27651444

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
STRADA0.905
ZNF8390.896
MAN1B10.895
SPG70.895
COQ40.894
ARFGAP10.884
ZNF4460.881
PPOX0.88
HKR10.88
PPIL20.874

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OR4F5-0.593
OR4F29-0.561
MTRNR2L9-0.377
MTRNR2L6-0.35
PGF-0.328
PABPC4L-0.318
MTRNR2L10-0.313
RAI14-0.312
ZNF114-0.31
KIAA0040-0.306

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PGAP3 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PGAP3 mRNA"27188386
D000082AcetaminophenAcetaminophen results in decreased expression of PGAP3 mRNA29067470
D000082AcetaminophenAcetaminophen affects the expression of PGAP3 mRNA17562736
D020106AcrylamideAcrylamide results in increased expression of PGAP3 mRNA28959563
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of PGAP3 mRNA26001963
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of PGAP3 mRNA22316170|2623829
C044887beta-methylcholinebeta-methylcholine affects the expression of PGAP3 mRNA21179406
C006780bisphenol A[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of PGAP3 mRNA28628672
C584509C646 compoundC646 compound results in increased expression of PGAP3 mRNA26191083
D016572CyclosporineCyclosporine results in decreased expression of PGAP3 mRNA25562108
D003907Dexamethasone[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of PGAP3 mRNA28628672
C000944dicrotophosdicrotophos results in decreased expression of PGAP3 mRNA28302478
C082360fipronilfipronil results in decreased expression of PGAP3 mRNA23962444
C492448ICG 001ICG 001 results in increased expression of PGAP3 mRNA26191083
D007213Indomethacin[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of PGAP3 mRNA28628672
D0150561-Methyl-3-isobutylxanthine[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of PGAP3 mRNA28628672
C004925methylmercuric chloridemethylmercuric chloride results in decreased expression of PGAP3 mRNA28001369
D018817N-Methyl-3,4-methylenedioxyamphetamine"N-Methyl-3,4-methylenedioxyamphetamine results in increased expression of PGAP3 mRNA"20188158
C006253pirinixic acid[pirinixic acid binds to and results in increased activity of PPARA protein] which results in increased expression of PGAP3 mRNA19710929
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of PGAP3 mRNA21570461
D014520UrethaneUrethane results in decreased expression of PGAP3 mRNA28818685
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PGAP3 mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of PGAP3 mRNA25979313
D014635Valproic AcidValproic Acid results in decreased expression of PGAP3 mRNA26272509|2915479

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0016788hydrolase activity, acting on ester bonds-IBA21873635  
GO:0016788hydrolase activity, acting on ester bonds-IMP17021251  
GO ID GO Term Qualifier Evidence PubMed
GO:0006505GPI anchor metabolic process-IMP17021251  
GO:0006506GPI anchor biosynthetic process-IBA21873635  
GO:0006506GPI anchor biosynthetic process-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0000139Golgi membrane-IEA-  
GO:0016021integral component of membrane-IEA-  
GO:0031227intrinsic component of endoplasmic reticulum membrane-IBA21873635  
GO:0031227intrinsic component of endoplasmic reticulum membrane-IDA12460457  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
27058054Asthma susceptibility variants are more strongly associated with clinically similar subgroups. (2016 Nov)Lavoie-Charland EJ Asthma